Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

ORTHO-ALLO-UNION ORTHOpaedic treatment with ALLOgenic combined ATMP in long bone fracture delayed UNION and non-union (ORTHO-ALLO-UNION).

Coordinator
Servicio Madrileno De Salud, Spain
Runs
1 December 2023 to 30 November 2028
Status
Running
EU funding
€10.6m
Total cost
€10.6m
Partners
21 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101137464

What the project is doing

In the project's own words, from its summary on CORDIS.

Bone fracture with delay or failure to heal is a condition with huge health impact. Although only a small proportion of long bone fractures evolve to non-union (5%), it is a first magnitude problem due to the number of new annual fractures and increasing incidence of complex fractures with high risk of non-consolidation, need for repeated procedures and years of patient disability. Bone autografts, autologous mesenchymal cells, or other complex interventions are used in this setting.

The aim of this project is the development of a universal therapy for fractures with delay or failure to heal, aiming to a simple and wide access to allogenic cell therapy combined with biomaterial, in a broad number of patients. Rather than considering ATMP only as a last solution in established non-union fractures, this project advocates that the indication should be moved to an earlier timepoint. Patients will be treated with the combined ATMP as soon as the need for reoperation is identified due to delayed healing, with or without an added infectious component, to avoid long-term suffering for patients and their relatives, and prevent progression to more severe non-unions, with heavy personal, social and economic costs.

This approach is aligned with the real needs of patients and better fits with the usual practice in the EU, where reoperations are performed at 6 months or before, in an attempt to accelerate bone healing and avoid complications. The project will establish a master cell bank for a wide allogenic production with donors selection criteria of bone formation potential. Necessary preclinical and clinical information to support the EU approval of a specific combined ATMP will be obtained.

Open access to scientific and regulatory information will be available for other EU medical device companies and cell therapy producers, so in addition to direct clinical benefit to patients and healthcare providers, other developers of combined ATMP products will get benefit.

Who is involved

OrganisationCityCountryRole
Servicio Madrileno De SaludMadridSpainCoordinator
Klinikum Der Ludwig-Maximilians-Universitat MunchenMunchenGermanyThird party
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyParticipant
Private Universitaet Witten/Herdecke gGmbHWittenGermanyThird party
Universitaet UlmUlmGermanyParticipant
Fundacion Para La Investigacion Biomedica Del Hospital Universiatrio La PazMadridSpainThird party
Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro-MajadahondaMajadahondaSpainThird party
Fundacion Para La Investigacion De Malaga En Biomedicina Y SaludMalagaSpainThird party
Pons Ip SAMadridSpainParticipant
Universidad Autonoma De MadridMadridSpainParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
BiomatlanteVigneux De BretagneFranceParticipant
Centre Hospitalier Regional Universitaire De ToursTours Cedex 9FranceParticipant
Ecrin European Clinical Research Infrastructure NetworkParisFranceParticipant
Etablissement Francais Du SangLa Plaine Saint DenisFranceParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Fondazione Irccs Ca' Granda - Ospedale Maggiore PoliclinicoMilanoItalyParticipant
Fondazione Policlinico Universitario Campus Bio MedicoRomaItalyParticipant
Istituto Ortopedico RizzoliBolognaItalyParticipant
Universita Degli Studi Di Modena E Reggio EmiliaModenaItalyParticipant
Universidade De AveiroAveiroPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI